Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review

Abstract

Asymptomatic elevation of the international normalized ratio (INR) is a common problem associated with hemorrhage. Evidence from randomized controlled trials supports the use of low-dose oral vitamin K therapy as a treatment that promptly reduces the INR. Vitamin K given orally is more effective than subcutaneous vitamin K injection, and as effective as intravenous administration when INR values are compared 24 hours after administration. A 1.0-mg vitamin K dose is likely most appropriate for patients with INR values between 4.5 and 10. The fear of over-correction of the INR has limited the widespread use of vitamin K; however, our review suggests that this occurs infrequently when small doses are administered orally.

Figures

Box 1

Fig. 1: Ampule of vitamin K. Because the tablet form of vitamin K is not currently available in Canada, the parenteral formulation can be given orally. It is dispensed in ampules of 0.5 mL (equivalent to 1.0 mg) and 1.0 mL (equivalent to 10.0 mg). The cost of treatment with 1.0 mg of parenteral vitamin K is as low as 10 cents when dispensed from an ampule of 10.0 mg/mL. Patient self-management may be a promising avenue for the use of oral vitamin K therapy in anticoagulation control.